Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Phase II Study With Lead-in Safety Cohort of Pembrolizumab (Keytruda®) and Trifluridine/Tipiracil (Lonsurf®) Combination Treatment in Patients With Previously Treated Advanced Gastric Cancer

NCT05508737 is registered in ClinicalTrials.gov with Yonsei University as lead sponsor.

NCT NCT05508737
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05508737 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Phase II Study With Lead-in Safety Cohort of Pembrolizumab (Keytruda®) and Trifluridine/Tipiracil (Lonsurf®) Combination Treatment in Patients With Previously Treated Advanced Gastric Cancer
Lead sponsor
Yonsei University
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
December 1, 2022
Completion date
December 1, 2025
Enrollment
75 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

gastric and gastroesophageal junction adenocarcinoma